Delpha Capital Management’s ResMed RMD Stock Holding History

Delpha Capital Management’s Portfolio RMD Stock Details RMD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q1	–	Sell	-146	Closed	-$12K	–	989
2017 Q4	$12K	Buy	+146	New	+$12.1K	0.01%	1006

Other funds holding RMD

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return

Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return

Norges Bank Oslo, Norway $1T AUM

Delpha Capital Management's RMD Position: Q1 2018 in Review

Delpha Capital Management sold out of ResMed (RMD) in Q1 2018, closing a stake of 146 shares — an estimated $12K sold.

Delpha Capital Management first reported a position in RMD in Q4 2017 and held it in 1 quarter. The position peaked at $12K in Q4 2017. 446 funds tracked by Wall St. Rank hold RMD as of Q1 2018.

Delpha Capital Management reported no remaining ResMed position as of Q1 2018 after selling out during the quarter.
Delpha Capital Management sold 146 ResMed shares in Q1 2018, an estimated $12K.
Delpha Capital Management first reported a position in ResMed in Q4 2017 and held it in 1 quarter.
Delpha Capital Management's ResMed position peaked at $12K in Q4 2017.
446 funds tracked by Wall St. Rank held ResMed as of Q1 2018.

Based on Delpha Capital Management's 13F filing for Q1 2018, filed 11 May 2018.